Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry
Authors:
- Gabriel E. GondolesiGGGabriel E. Gondolesi
- Ulrich-Frank PapeUPUlrich-Frank Pape
- Joel B. MasonJMJoel B. Mason
- Johane P. AllardJAJohane P. Allard
- Loris PironiLPLoris Pironi
- María Núria Virgili CasasMCMaría Núria Virgili Casas
- Lauren K. SchwartzLSLauren K. Schwartz
- Francisca JolyFJFrancisca Joly
- André GabrielAGAndré Gabriel
- Sasan SabrdaranSSSasan Sabrdaran
- Pinggao ZhangPZPinggao Zhang
- Martina Kohl-SobaniaMKMartina Kohl-Sobania
Open Access
Abstract
The Short Bowel Syndrome (SBS) Registry (NCT01990040) is a multinational real-world study evaluating the long-term safety of teduglutide in patients with SBS and intestinal failure (SBS-IF) in routine clinical practice. This paper describes the study methodology and baseline characteristics of adult patients who have (ever-treated) or have never (never-treated) received teduglutide. A total of 1411 adult patients (679 ever-treated; 732 never-treated) were enrolled at 124 sites across 17 countries. The mean (standard deviation [SD]) age at enrollment was 55.4 (15.46) years, and 60.2% of patients were women. Crohn’s disease was the most common cause of major intestinal resection in both ever-treated (34.1%) and never-treated patients (20.4%). A similar proportion of ever-treated and never-treated patients had a prior history of colorectal polyps (2.7% vs. 3.6%), whereas proportionally fewer ever-treated patients reported a history of colorectal cancer (1.8% vs. 6.2%) or any malignancy (17.7% vs. 30.0%) than never-treated patients. Never-treated patients received a numerically greater mean (SD) volume of parenteral nutrition and/or intravenous fluids than ever-treated patients (12.4 [8.02] vs. 10.1 [6.64] L/week). Ever-treated patients received a mean teduglutide dosage of 0.05 mg/kg/day. This is the first report of patient baseline characteristics from the SBS Registry, and the largest cohort of patients with SBS-IF to date. Overall, ever-treated and never-treated patients had similar baseline characteristics. Differences between treatment groups may reflect variations in patient selection and degree of monitoring.Keywords
Funding Information
- Takeda Pharmaceuticals International, Inc., USA. (NA)
This publication has 44 references indexed in Scilit:
- Short bowel syndrome: Complications and managementNutrition in Clinical Practice, 2023
- Etiologies and treatments of chronic intestinal failure-short bowel syndrome (SBS) in Japanese adults: a real-world observational studySurgery Today, 2022
- Teduglutide in short bowel syndrome patients: A way back to normal life?Journal of Parenteral and Enteral Nutrition, 2021
- Characterization of American teduglutide consumers from 2015 to 2020: A large database studyJournal of Parenteral and Enteral Nutrition, 2021
- Safety Findings in Pediatric Patients During Long‐Term Treatment With Teduglutide for Short‐Bowel Syndrome–Associated Intestinal Failure: Pooled Analysis of 4 Clinical StudiesJournal of Parenteral and Enteral Nutrition, 2020
- De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short‐Bowel Syndrome: A Case ReportJournal of Parenteral and Enteral Nutrition, 2020
- Long‐Term Outcomes With Teduglutide From a Single CenterJournal of Parenteral and Enteral Nutrition, 2020
- Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III StudyJournal of Parenteral and Enteral Nutrition, 2019
- Reduction of Parenteral Nutrition and Hydration Support and Safety With Long‐Term Teduglutide Treatment in Patients With Short Bowel Syndrome−Associated Intestinal Failure: STEPS‐3 StudyNutrition in Clinical Practice, 2018
- Long‐Term Therapy With Teduglutide in Parenteral Support–Dependent Patients With Short Bowel Syndrome: A Case SeriesJournal of Parenteral and Enteral Nutrition, 2018